Alkem Laboratories 2026 Forecast | Price, Valuation & Growth

Alkem Laboratories

NSEI:ALKEM

Rp 5.435,50

Rp0,00 (0,00%)

5.435,50 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

Alkem Laboratories Stock Value

Analysts currently rate NSEI:ALKEM as Hold.

Hold

Alkem Laboratories Company Info

EPS Growth 5Y

13,95%

Market Cap

Rp649,90 B

Long-Term Debt

Rp3,11 B

Annual earnings

05/16/2026 (E)

Dividend

Rp45,11

Dividend Yield

0,83%

Founded

1973

Industry

Health Care

Country

India

Website

Alkem Laboratories

ISIN Number

INE540L01014

Website

http://www.alkemlabs.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp5.962,00

9.69%

Last Update: 03/28/2026

Analysts: 21

Highest Price Target Rp6.913,00

Average Price Target Rp5.962,00

Lowest Price Target Rp4.360,00

In the last five quarters, Alkem Laboratories’s Price Target has risen from Rp4.866,42 to Rp5.152,57 - a 5,88% increase. Eighteen analysts predict that Alkem Laboratories’s share price will increase in the coming year, reaching Rp5.962,00. This would represent an increase of 9,69%.

Top growth stocks in the health care sector (5Y.)

What does Alkem Laboratories do?

Alkem Laboratories Limited a pharmaceutical company that engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products. Business Segments The company operates through Prescription Medications, Generic Drugs, and Over the Counter (OTC) Products segments. Prescription Medications This segment represents a significant portion of the company’s offerings. This segment encompasses various therapeutic categories, including antibiotics, cardiovascular me...

Alkem Laboratories Limited a pharmaceutical company that engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products.

Business Segments

The company operates through Prescription Medications, Generic Drugs, and Over the Counter (OTC) Products segments.

Prescription Medications

This segment represents a significant portion of the company’s offerings. This segment encompasses various therapeutic categories, including antibiotics, cardiovascular medications, and anti-diabetic drugs. The company invests heavily in research and development to enhance the effectiveness and safety profiles of its prescription medications. The segment's success is attributed to the company's strong relationships with healthcare professionals and its commitment to understanding patient needs.

Generic Drugs

This segment provides high-quality alternatives to branded medications. This endeavor not only makes essential medicines more accessible and affordable but helps to expand the company’s footprint in various international markets. The company places a strong emphasis on compliance and quality assurance in this segment to ensure that its generic offerings meet or exceed regulatory standards.

Over the Counter (OTC) Products

This segment includes a wide array of health and wellness products for consumers without the need for a prescription. This segment includes dietary supplements, personal care items, and other non-prescription healthcare products. The company's strategic initiatives in marketing and brand positioning have enabled it to capture significant market share in this rapidly growing segment.

Business Strategy

The company's overarching business strategy is centered on delivering high-quality, effective pharmaceutical solutions while enhancing operational efficiencies. The company adopts a multi-faceted approach that includes innovation, strategic partnerships, and geographical expansion as critical components of its strategic framework.

Innovation is at the forefront of the company's business strategy. The company allocates significant resources to research and development, aimed at discovering and developing novel therapeutic solutions. By focusing on advanced drug formulation and leveraging cutting-edge technology, the company strives to improve existing products and invent new ones that address prevalent and emerging health challenges.

Strategic partnerships and collaborations play a vital role in expanding the company’s product portfolio and market reach. By forging alliances with academia, research organizations, and other pharmaceutical companies, the company enriches its scientific expertise while penetrating new markets. This collaborative approach allows the company to share risks and bring innovative products to market more effectively.

Geographical expansion is another pillar of the company’s strategy. By penetrating international markets, particularly in regulated territories, the company is enhancing its brand reputation while driving revenue growth. The company continuously evaluates and enters new markets where demand for its products exists, thus broadening its global footprint.

Additionally, the company emphasizes sustainability and corporate responsibility within its strategic framework. By integrating sustainable practices across its operations, the company is committed to minimizing its environmental impact while maintaining high standards of compliance and governance.

Products and Services

The company offers a broad range of products and services that fall into several categories. The company's primary offerings include prescription medications, generic formulations, over-the-counter products, and nutraceuticals.

The prescription medications portfolio spans multiple therapeutic areas, including antibiotics, anti-inflammatory drugs, cardiovascular medicines, anti-diabetic drugs, and dermatological products. This extensive range is a result of the company’s rigorous R&D programs, aimed at meeting the complex needs of healthcare providers and patients.

In addition, the generic drugs segment includes a variety of generic formulations that provide cost-effective alternatives to branded medications. This segment is crucial for increasing accessibility to essential medications, particularly in developing markets.

The over-the-counter product line encompasses various health and wellness solutions, tailored for consumer use. This includes dietary supplements, analgesics, and personal care items that appeal directly to consumers seeking relief for common ailments.

Furthermore, the company emphasizes the importance of providing extensive information and consultations to healthcare practitioners, aiding in the effective use of its products.

Geographical Markets

The company serves a vast geographical market that spans domestic and international territories. Its primary market is India, where it maintains a commanding presence in the pharmaceutical sector. Furthermore, the company has successfully established itself in global markets, particularly in the United States and various other countries, expanding the accessibility of its products to a wider audience.

Customers

The company serves a diverse customer base, which includes healthcare providers, pharmacies, hospitals, and direct consumers. The company focuses on delivering high-quality products tailored to meet the specific needs of each segment. By investing in relationships with healthcare professionals, the company enhances its service offerings and ensures that its products are effectively utilized in clinical settings.

Sales and Marketing

The company employs a multifaceted approach to sales and marketing that includes a blend of direct sales teams, digital marketing, and partnerships with distributors. This strategy allows the company to effectively reach its target customer segments, enhancing engagement and facilitating sales. The integration of digital platforms into marketing efforts has broadening its outreach and connectivity with consumers and healthcare professionals alike.

History

Alkem Laboratories Limited was founded in 1973. The company was incorporated in 1973.

Alkem Laboratories Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Products:** 80% **Dietary Supplements:** 15% **Other Health Products:** 5% **Top 3 Markets:** 1. **India:** 65% 2. **USA:** 20% 3. **Europe:** 10% Alkem Laboratories Limited generates the majority of its revenue from the sale of pharmaceutical products, accounting fo...

At which locations are the company’s products manufactured?

**Production sites of Alkem Laboratories Limited:** Alkem Laboratories Limited operates several production facilities in India, including at the following locations: 1. **Daman** 2. **Baddi, Himachal Pradesh** 3. **Ankleshwar, Gujarat** 4. **Mandva, Gujarat** 5. **Sikkim** These production sites...

What strategy does Alkem Laboratories pursue for future growth?

**Revenue Growth:** 10.5% (estimated 2024) **Research & Development (R&D) Expenses:** 8% of revenue (estimated 2024) Alkem Laboratories Limited pursues a growth strategy that heavily relies on research and development to develop innovative pharmaceutical products. The company continuous...

Which raw materials are imported and from which countries?

**Main raw materials:** Active pharmaceutical ingredients (APIs), excipients **Main importing countries:** China, Germany, USA Alkem Laboratories Limited mainly imports active pharmaceutical ingredients (APIs) and excipients needed for the production of their medications. A significant portion of...

How strong is the company’s competitive advantage?

**Market share in India:** 3.5% (2024) **R&D expenses:** 6.2% of revenue (2024) **Export growth:** 10% (2024) Alkem Laboratories Limited has a significant competitive advantage due to its strong presence in the Indian pharmaceutical market, where it ranks among the top 10 companies. The company...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approx. 25% (2025, estimated) **Insider Buys/Sells:** No significant changes in the last year (2025, estimated) The institutional investor share in Alkem Laboratories Limited is approximately 25%. This demonstrates the confidence of institutional investors in the...

What percentage market share does Alkem Laboratories have?

**Market share of Alkem Laboratories:** Estimated 4-5% (2025) **Top competitors and their market shares:** 1. **Sun Pharmaceutical Industries:** Approx. 8-10% 2. **Cipla Limited:** Approx. 7-9% 3. **Dr. Reddy's Laboratories:** Approx. 6-8% 4. **Lupin Limited:** Approx. 5-7% 5. **Aurobindo Phar...

Is Alkem Laboratories stock currently a good investment?

**Revenue Growth:** 10% (2024) **Profit Growth:** 8% (2024) **Research and Development Expenses:** 7% of Revenue (2024) Alkem Laboratories Limited recorded a revenue growth of 10% in 2024, attributed to strong demand for their pharmaceutical products. The company also achieved a profit growth of 8%...

Does Alkem Laboratories pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.8% (2024) **Dividend growth:** 5% (last 3 years) **Payout ratio:** 40% (2024) Alkem Laboratories Limited has been regularly paying dividends in recent years. The current dividend yield is approximately 1.8%, which is moderate compared to other companies in the industry. The 4...

New support ticket

Explore

Alkem Laboratories Stock Value

Alkem Laboratories Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Alkem Laboratories do?

Alkem Laboratories Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Alkem Laboratories Stock Value

Alkem Laboratories Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Alkem Laboratories do?

Alkem Laboratories Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.